Sai Life Sciences Limited is an integrated CRDMO offering end-to-end services across drug discovery, development, and manufacturing. The company serves global pharmaceutical innovators, providing integrated solutions.

In the latest financial quarter, Sai Life Sciences achieved a 36% revenue growth year-on-year with a revenue of ₹537 crore, reflecting strong performance in both their CRO and CDMO services.

The company is executing a substantial capacity expansion plan from 700 KL to 1150 KL by FY27, supported by a planned capex of ₹700 crore in FY26, enhancing R&D and manufacturing capabilities.

Strategic collaborations with UK-based firms are allowing Sai to extend its CMC offerings globally, demonstrating an international growth strategy and broadening its service portfolio.

Sai Life Sciences is leading in adopting new technologies and modalities like peptides, ADCs, and oligonucleotides to stay ahead in the competitive CRDMO market, enhancing their innovation pipeline and capability spectrum.